Eli Lilly and Company, Abbott Laboratories, and JD.com are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies whose core business involves researching, developing, manufacturing and marketing prescription drugs, vaccines and other medical therapies. Their market value is heavily influenced by clinical trial outcomes, regulatory approvals and patent lifecycles. Investors often buy these stocks to gain exposure to the healthcare and biotech sector, balancing potential high returns against the risks of costly R&D and stringent oversight. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of Eli Lilly and Company stock traded up $19.55 during trading on Thursday, hitting $680.04. 5,368,983 shares of the company were exchanged, compared to its average volume of 4,116,507. The firm has a 50 day moving average price of $767.52 and a 200 day moving average price of $796.25. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $972.53. The stock has a market capitalization of $643.63 billion, a price-to-earnings ratio of 44.50, a P/E/G ratio of 0.90 and a beta of 0.44.
Read Our Latest Research Report on LLY
Abbott Laboratories (ABT)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Shares of Abbott Laboratories stock traded up $0.02 during trading on Thursday, reaching $129.42. The company had a trading volume of 6,662,213 shares, compared to its average volume of 6,879,370. The company has a market cap of $225.24 billion, a price-to-earnings ratio of 16.21, a price-to-earnings-growth ratio of 2.48 and a beta of 0.70. Abbott Laboratories has a fifty-two week low of $109.76 and a fifty-two week high of $141.23. The firm's fifty day moving average is $131.52 and its 200-day moving average is $131.15. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82.
Read Our Latest Research Report on ABT
JD.com (JD)
JD.com, Inc. operates as a supply chain-based technology and service provider in the People's Republic of China. The company offers computers, communication, and consumer electronics products, as well as home appliances; and general merchandise products comprising food, beverage and fresh produce, baby and maternity products, furniture and household goods, cosmetics and other personal care items, pharmaceutical and healthcare products, industrial products, books, automobile accessories, apparel and footwear, bags, and jewelry.
NASDAQ:JD traded down $0.71 during trading hours on Thursday, reaching $31.81. 18,600,604 shares of the company's stock were exchanged, compared to its average volume of 12,426,964. The business's 50-day simple moving average is $32.46 and its two-hundred day simple moving average is $36.01. JD.com has a 12 month low of $25.24 and a 12 month high of $47.82. The company has a quick ratio of 0.92, a current ratio of 1.26 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $44.42 billion, a P/E ratio of 7.75, a price-to-earnings-growth ratio of 4.19 and a beta of 0.46.
Read Our Latest Research Report on JD
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
MarketBeat All Access